ストックスクリーナーアプリを入手
0.00
100.00%
-15.96
Cara Therapeutics Inc (CARA) 最新ニュース
Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire
This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance
This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com
Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire
Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia
Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria
Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener
Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria
Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest
Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener
Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener
Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
How To Trade (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Where are the Opportunities in (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
0.71%
0.30%
大文字化:
|
ボリューム (24 時間):